Publication:
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

dc.contributor.authorBastard, P.
dc.contributor.authorGervais, A.
dc.contributor.authorTaniguchi, M.
dc.contributor.authorSaare, L.
dc.contributor.authorSärekannu, K.
dc.contributor.authorVoyer, T.L.
dc.contributor.authorPhilippot, Q.
dc.contributor.authorRosain, J.
dc.contributor.authorBizien, L.
dc.contributor.authorAsano, T.
dc.contributor.authorGarcia-Prat, M.
dc.contributor.authorParra-Martínez, A.
dc.contributor.authorMigaud, M.
dc.contributor.authorTsumura, M.
dc.contributor.authorConti, F.
dc.contributor.authorBelot, A.
dc.contributor.authorRivière, J.G.
dc.contributor.authorMorio, T.
dc.contributor.authorTanaka, J.
dc.contributor.authorJavouhey, E.
dc.contributor.authorHaerynck, F.
dc.contributor.authorDuvlis, S.
dc.contributor.authorÖzcelik, T.
dc.contributor.authorKeles, S.
dc.contributor.authorTandjaoui-Lambiotte ,Y.
dc.contributor.authorEscoda, S.
dc.contributor.authorHusain, M.
dc.contributor.authorPan-Hammarström, Q.
dc.contributor.authorHammarström, L.
dc.contributor.authorAhlijah, G.
dc.contributor.authorHaidar ,A.A.
dc.contributor.authorSoudee, C.
dc.contributor.authorArseguel, V.
dc.contributor.authorAbolhassani, H.
dc.contributor.authorSahanic, S.
dc.contributor.authorTancevski, I.
dc.contributor.authorNukui ,Y.
dc.contributor.authorHayakawa, S.
dc.contributor.authorChrousos, G.P.
dc.contributor.authorMichos, A.
dc.contributor.authorTatsi ,E.B.
dc.contributor.authorFilippatos, F.
dc.contributor.authorRodriguez-Palmero, A.
dc.contributor.authorTroya, J.
dc.contributor.authorTipu, I.
dc.contributor.authorMeyts, I.
dc.contributor.authorRoussel, L.
dc.contributor.authorOstrowski, S.R.
dc.contributor.authorSchidlowski,L.
dc.contributor.authorPrando, C.
dc.contributor.authorCondino-Neto, A.
dc.contributor.authorCheikh, N.
dc.contributor.authorBousfiha, A.A.
dc.contributor.authorBakkouri, J.E.
dc.contributor.authorPeterson, P.
dc.contributor.authorPujol, A.
dc.contributor.authorLévy, R.
dc.contributor.authorQuartier, P.
dc.contributor.authorVinh, D.C.
dc.contributor.authorBoisson, B.
dc.contributor.authorBéziat, V.
dc.contributor.authorZhang, S.Y.
dc.contributor.authorBorghesi, A.
dc.contributor.authorPession, A.
dc.contributor.authorAndreakos, E.
dc.contributor.authorMarr, N.
dc.contributor.authorMentis, A.F.A.
dc.contributor.authorH.mogensen, T.
dc.contributor.authorRodríguez-Gallego, C.
dc.contributor.authorSoler-Palacin, P.
dc.contributor.authorColobran, R.
dc.contributor.authorTillmann, V.
dc.contributor.authorNeven, B.
dc.contributor.authorTrouillet-Assant, S.
dc.contributor.authorBrodin, P.
dc.contributor.authorAbel, L.
dc.contributor.authorJouanguy, E.
dc.contributor.authorZhang, Q.
dc.contributor.authorMartinón-Torres, F.
dc.contributor.authorSalas, A.
dc.contributor.authorGómez-Carballa, A.
dc.contributor.authorGonzalez-Granado, L.I.
dc.contributor.authorKisand, K.
dc.contributor.authorOkada, S.
dc.contributor.authorPuel, A.
dc.contributor.authorCobat, A.
dc.contributor.authorCasanova, J.L.
dc.contributor.authorAguilera-Albesa, S.
dc.contributor.authorAlkhater, S.A.
dc.contributor.authorAlkan, G.
dc.contributor.authorCastagnoli, R.
dc.contributor.authorCyrus, C.
dc.contributor.authorBozdemir, S.E.
dc.contributor.authorEmiroglu, M.
dc.contributor.authorGulhan, B.
dc.contributor.authorErdeniz, E.H.
dc.contributor.authorHatipoglu, N.
dc.contributor.authorBayhan,G.I.
dc.contributor.authorJabandziev, P.
dc.contributor.authorYuksek, S.K.
dc.contributor.buuauthorTEMEL, ŞEHİME GÜLSÜN
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıbbi Genetik Ana Bilim Dalı
dc.date.accessioned2025-05-12T22:39:02Z
dc.date.issued2024-01-01
dc.description.abstractWe found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7–9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2–5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6–35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1–9.6]) of IFN-ω and/or IFN-α2.
dc.description.sponsorshipSquare Foundation
dc.description.sponsorshipBattersea & Bowery Advisory Group
dc.description.sponsorshipBGI Genomics
dc.description.sponsorshipInstitut National de la Santé et de la Recherche Médicale
dc.description.sponsorshipANR AAILC
dc.description.sponsorshipKnut och Alice Wallenbergs Stiftelse
dc.description.sponsorshipGeneral Atlantic Foundation
dc.description.sponsorshipAustralasian Centre for Italian Studies
dc.description.sponsorshipFonds de Recherche du Québec - Santé
dc.description.sponsorshipGeneralitat de Catalunya
dc.description.sponsorshipFondation Bettencourt Schueller
dc.description.sponsorshipBI-BACVIR
dc.description.sponsorshipFondation du Souffle
dc.description.sponsorshipCovidPhy
dc.description.sponsorshipSt. Giles Foundation
dc.description.sponsorshipFonds Wetenschappelijk Onderzoek
dc.description.sponsorshipFisher Center for Alzheimer's Research Foundation
dc.description.sponsorshipELIDEK
dc.description.sponsorshipEuropean Commission
dc.description.sponsorshipMerck Canada
dc.description.sponsorshipAgencia Estatal de Investigación
dc.description.sponsorshipRockefeller University
dc.description.sponsorshipJPB Foundation
dc.description.sponsorshipUniversity of Paris Cité and Imagine Institute
dc.description.sponsorshipStavros Niarchos Foundation Institute for Global Infectious Disease Research
dc.description.sponsorshipGlenn Foundation for Medical Research
dc.description.sponsorshipFondation Meyer pour le Développement Culturel et Artistique
dc.description.sponsorshipVetenskapsrådet
dc.description.sponsorshipHoward Hughes Medical Institute
dc.description.sponsorshipMinistry of Education, Culture, Sports, Science and Technology
dc.description.sponsorshipEuropean Research Council See opportunities (opens in new window) HORIZON-HLTL-2021-ID, 101057100
dc.description.sponsorshipOMI-COVI-VAC PI22/00406
dc.description.sponsorshipMinistry of Higher Education, Research and Innovation See opportunities by MoHERI See opportunities (opens in new window) MESRI-COVID-19
dc.description.sponsorshipFundación Canaria Instituto de Investigación Sanitaria de Canarias
dc.description.sponsorshipFundación Canaria Instituto de Investigación Sanitaria de Canarias FIISC19/43, OA18/017, PIFIISC22/27
dc.description.sponsorshipOperational Program Competitiveness, Entrepreneurship and Innovation T2EDK-02222
dc.identifier.doi10.1084/jem.20231353
dc.identifier.issn0022-1007
dc.identifier.issue2
dc.identifier.scopus2-s2.0-85181628485
dc.identifier.urihttps://hdl.handle.net/11452/51420
dc.identifier.volume221
dc.indexed.scopusScopus
dc.language.isoen
dc.publisherRockefeller University Press
dc.relation.journalJournal of Experimental Medicine
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectInnate immunity and inflammation
dc.subjectInfectious disease and host defense
dc.subjectImmunodeficiency
dc.subjectCOVID-19
dc.subject.scopusSARS Coronavirus; Interferon Type I; COVID-19
dc.titleHigher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültei/Tıbbi Genetik Ana Bilim Dalı
relation.isAuthorOfPublicationf513efaa-a54e-4cfa-840f-28e2fbdc001a
relation.isAuthorOfPublication.latestForDiscoveryf513efaa-a54e-4cfa-840f-28e2fbdc001a

Files

Collections